Surgical Mask Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Surgical mask sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹6.6 crore - ₹110 crore CapEx this DPR captures:

• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016
• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The surgical mask sector in India spans both the organized and unorganized segments, with the unorganized segment historically dominating through a high concentration of fragmented small and medium-sized enterprises. Individual plant production capacities in the SME tier typically range between 10,000 and 100,000 masks per day, while automated facilities can achieve annual production capacities between 100 million and 500 million pieces. Offline distribution channels, including hospital pharmacies, medical supply stores, and retail stores, account for approximately 72.4% of market share, highlighting the reliance on traditional physical retail networks.

The protective masks segment held a dominant revenue share of 35.64% in 2023 within the broader Indian mask market. North India leads regional demand with approximately 29% market share, making it the most attractive location for new manufacturing capacity. Key demand drivers include ongoing infection control protocols in hospitals mandating sterile environments, rising healthcare expenditure and expanding hospital infrastructure, and increased public awareness of airborne disease transmission risks.

The Asia Pacific region commanded 38.2% of global three-dimensional surgical face mask revenue in 2025, with a projected CAGR of 9.13% through 2034 driven by domestic manufacturing expansion across the region.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>The core manufacturing technology for 3-ply surgical masks relies on the Spunbond-Meltblown-Spunbond (SMS) process, a three-layer composite structure that balances barrier protection with breathability. The outer and inner layers are produced using spunbond polypropylene (PP) fabric at a typical density of 20 grams per square meter (gsm), manufactured by extruding melted plastic into continuous filaments deposited on a conveyor. The middle filtration layer employs the meltblown method, wherein molten polymer is blown through fine nozzles with hot air to create microfibers that serve as the critical filtration barrier.

Spunbond fabrics for this application typically range from 10 to 50 gsm, with 20 to 25 gsm being the industry standard for surgical masks. Automated manufacturing lines have evolved significantly, with legacy lines operating at 500 to 1,000 masks per minute, while modern high-speed automated lines deliver substantially higher throughput. The global automatic mask production equipment market was valued at USD 5.86 billion in 2024 and is projected to expand to USD 16.08 billion by 2035 at a CAGR of 9.61%.

Domestically, fully automatic 3-ply mask making machines are available from suppliers such as Global Industries in Noida and Star Industries in Patna at prices between INR 7,50,000 and INR 9,00,000 per unit (2025 rates), while Startup Machinery India in Patna offers machines at INR 9,99,990 per unit. Saral Design Solutions in Mumbai repurposed automated machinery to manufacture low-cost SITRA-certified 3-ply surgical masks using Spunmelt (SSMMS) filters under the SWACHH initiative in 2020, demonstrating indigenous innovation potential. KARAM Industries in New Delhi launched IS 16289:2014 certified surgical masks following its diversification into the healthcare sector.

India imports the majority of its mask-making machinery from Taiwan, which holds a 61.60% market share of total mask-making machinery imports, followed by China at 38.12%, with primary import HS Codes including 84798999, 84490090, 84799090, and 84518090.</p>

The project financial architecture recommends debt-to-equity ratios of 60:40 for the ₹6.6-20 crore CapEx band and 70:30 for larger ₹20-110 crore facilities to optimise weighted average cost of capital. For projects in the ₹45 crore CapEx range, SIDBI Term Loan access at MCLR+ 150-200 basis points provides competitive financing, supplemented by healthcare-specific credit products from Axis Bank Healthcare Finance and ICICI Bank Medical Equipment loans. State-linked incentive schemes including Gujarat's Mukhya Mantri Udhyog Yojana and Tamil Nadu's EV Priority Sector incentive offset 15-25% of CapEx through SGST reimbursement and capital subsidy structures. Working capital requirements for a ₹45 crore facility producing 2.4 million masks monthly approximate 45-60 days of raw material inventory (meltblown fleece, spunbond, elastic, nose wire), 15-25 days of WIP, and 30-40 days of finished goods buffer ahead of institutional tender cycles. This translates to ₹18-22 crore of working capital facility requirement, addressable via Axis Bank or HDFC Bank Cash Management Credit with receivables insurance coverage. PLI Scheme for Medical Devices provides 5% incentive on incremental sales exports, with demonstrated export realisation from 3M India's Hyderabad facility achieving ₹120 crore annual export billing to US healthcare systems. Break-even analysis for a mid-scale ₹45 crore project indicates operational break-even at 72% capacity utilisation with EBITDA margin of 22-26% at ASP of ₹5.5-6 per mask. The payback period of 2.8-5.2 years across scale scenarios aligns with SIDBI's typical 7-year tenor for healthcare manufacturing loans.

<p>Several material risks confront surgical mask plant operators in India that require careful mitigation planning. Raw material dependency poses the most significant supply chain vulnerability, as production relies on specialized polypropylene (PP) non-woven fabrics, specifically 20 to 25 gsm densities produced via spunbond and meltblown technologies. Historical demand surges, particularly during pandemic periods, triggered severe shortages of meltblown fabric, which constitutes the critical filtration layer, with raw material consumption of non-woven meltblown fabric accounting for 50% to 60% of total operational expenditures and utility costs adding a further 15% to 20%.

Taiwan and China together account for nearly 100% of mask-making machinery imports into India, with Taiwan at 61.60% and China at 38.12%, creating geopolitical supply chain exposure for equipment sourcing and spare parts. The market faces functional substitution risk from N95, FFP2, and KN95 respirators that serve as higher-grade alternatives in medical and industrial settings, as well as reusable cloth and fabric masks that compete in the consumer segment. The unorganized segment's dominance by fragmented SMEs with basic automation creates intense price competition that can compress margins for organized players.

Demand volatility remains a concern, as the market experienced an extraordinary boom-and-bust cycle during the COVID-19 pandemic, with post-pandemic demand normalizing significantly from peak levels. Sustainability and environmental compliance pressures are growing, as the single-use nature of disposable masks attracts regulatory and public scrutiny, though leading global manufacturers such as Makrite are addressing this through energy-efficient machinery, renewable energy adoption via solar and wind power, and waste heat recovery systems, while Intersurgical operates under ISO 14001:2015 environmental management standards.</p>